Symic Bio to Present at the BioCentury 25th Annual Future Leaders Conference in New York

SAN FRANCISCO, March 15, 2018 /PRNewswire/ -- Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline at the BioCentury 25^th Annual Future Leaders in the Biotech Industry Conference in New York.

Presentation details are as follows:

 Date: Friday, March 23, 2018 Time: 3:30 p.m. EDT Location: Millennium Broadway Hotel & Conference Center, New York 

About Symic Bio

Symic Bio is a biopharmaceutical company developing novel matrix regulators, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-061, directed at disease modification and pain management in the treatment of osteoarthritis, and SB-030, targeting the prevention of peripheral vein graft failure. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company’s website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

CONTACT: Investor Contact: Gitanjali Jain Ogawa, The Trout Group, (646) 378-2949 gogawa@troutgroup.com or Media Contacts: David Schull or Rich Allan, Russo Partners, LLC, (212) 845-4271, (646) 942-5588, david.schull@russopartnersllc.com, rich.allan@russopartnersllc.com